About Cardiosense
Cardiosense is a medical technology company that leverages wearable sensing technology, advanced signal processing, and deep learning to transform physiological data into actionable clinical insight for cardiovascular disease management. The company's flagship product, which recently received FDA De Novo approval, is the first and only heart failure monitoring solution to determine Pulmonary Capillary Wedge Pressure (PCWP) noninvasively at point-of-care. The CardioTag wireless sensor and PCWP Analysis Software enable clinicians to more precisely and proactively manage heart failure patients across all care settings—from emergency departments and inpatient facilities to outpatient clinics and home monitoring. By providing quantitative PCWP readings in minutes, Cardiosense enables early detection and intervention weeks before fluid builds up and symptoms arise, helping reduce heart failure hospitalizations and improve long-term patient outcomes. The technology is validated against right heart catheterization with accuracy on par with implantable sensors, offering a rapid, easy-to-use alternative that eliminates guesswork in heart failure management. Founded by engineers and scientists, Cardiosense's AI platform addresses complex cardiovascular challenges by converting raw physiological data into clinical intelligence, providing both clinicians and patients with tools for precise, proactive disease management.
Mission & Story
Founding Story
Founded by engineers and scientists who developed wearable technology, signal processing, and deep learning capabilities to diagnose and assess cardiovascular disease. The core technology was developed from research conducted by co-founder Omer Inan at Georgia Tech, where Andrew Carek worked in Inan's Research Lab developing wearable technologies that leverage mechanical signals of the heart to non-invasively derive blood pressure.
Clinical Focus
Medical conditions and clinical areas addressed by Cardiosense.
Who It Serves
Milestones & Awards
Recent Milestones
FDA De Novo Classification received in 2025 for novel cardiac technology. New CEO Eric Meizlish and CMO Dr. John D. Martin joined in 2025. Raised approximately $30M in funding through 2025.
Awards & Recognition
Co-founder Omer Inan received Academy Award for Technical Achievement from The Academy of Motion Picture Arts and Sciences (The Oscars) for audio engineering work. Inan is Fellow of IEEE, AIMBE, and American College of Cardiology, and received NSF CAREER award, ONR Young Investigator award, and IEEE Sensors Council Early Career award.
Social & Media
Latest Updates
Cardiosense Appoints Eric Meizlish as CEO to Advance AI-Enabled Cardiac Care
Cardiosense Presents New Clinical Analysis of SEISMIC-HF I Data on AI-Enabled Volume Assessment in Heart Failure at the Transcatheter Cardiovascular Therapeutics (TCT) 2025 Scientific Symposium
FDA clears catheter-free heart failure monitor
Cardiosense Launches Nationwide SEISMIC-HF II Study to Validate Its AI Algorithm for Non-Invasive Heart Failure Management
Cardiosense Announces Publication of SEISMIC-HF I Study Results in the Journal of the American College of Cardiology: Heart Failure
Company Details
- Founded
- 2020
- Headquarters
- Chicago, IL, USA
- Employees
- 1-10
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
AccurKardia
AI-powered platform for cardiovascular disease detection and cardiac risk assessment.
Acorai
AI platform for cardiovascular disease detection and cardiac risk assessment.
Aisap
11-50 employees
AISAP provides FDA-cleared AI-powered diagnostic algorithms embedded in an operating system for point-of-care ultrasound (POCUS) devices. The platform enables rapid, expert-level cardiac imaging interpretation at the bedside, helping physicians detect structural heart disease early and make faster clinical decisions across hospitals, clinics, and screening programs.
AliveCor
AliveCor develops FDA-cleared, AI-powered ECG devices and software platforms for cardiac monitoring. The company offers portable ECG solutions ranging from consumer personal devices to clinical-grade 12-lead systems, serving patients, healthcare providers, biopharma companies, and health systems with remote and connected cardiac care.
Anumana AI
series c · 175 employees
Anumana AI develops and delivers AI-driven ECG algorithms to enable early diagnosis and intervention for cardiovascular conditions.
Artrya
11-50 employees
Artrya develops AI-powered solutions for rapid assessment of chest pain patients in emergency and primary care settings. The company's technology analyzes coronary computed tomography angiography (CCTA) to detect arterial plaque and stratify patient risk within minutes.
Bay Labs
Bay Labs is a health AI company focused on cardiology and cardiovascular health. The company's website is currently under construction with limited public information available.
BunkerHill Health
Bunkerhill Health provides Carebricks, an AI-powered platform that enables health systems to design, deploy, and operationalize AI agents across clinical and operational workflows. The platform reasons across patient data and automates actions within existing EHR systems.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.